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The compound �-methylguanidino acetic acid was first described in the year 
1835 and was named creatine (Figure 1). Creatine biosynthesis and metabolism have 
been studied for about 100 years and their importance has been recognized since then.
Figure 1. Chemical structure of creatine. 
Creatine is distributed throughout the body: 95% of the creatine pool is found in 
skeletal muscle, while the remaining 5% is found in brain, liver, kidney and testis [1]. 
Creatine body content is maintained by both nutritional intake (50%) and biosynthesis 
(50%).
Creatine biosynthesis involves a two-step reaction. The first, which is rate 
limiting, is catalyzed by arginine:glycine amidinotransferase (AGAT, EC 2.1.4.1) and 
involves the transfer of the amidino group of arginine to glycine, yielding ornithine and 
guanidinoacetic acid. In the second step, guanidinoacetic acid is methylated into 
creatine by guanidinoacetate methyltransferase (GAMT, EC 2.1.1.2) [1,2] (Figure 2). 
Creatine is distributed via the blood stream and taken up in the different tissues by the 
creatine transporter (SLC6A8) (Figure 2, insert). Creatine kinase catalyses the 
phosphorylation and dephosphorylation of creatine and phosphocreatine, respectively, 
providing a high energy phosphate buffering system during adenosine triphosphate 
release and use [3]. Intracellular creatine and phosphocreatine are non-enzymatically 
converted to creatinine with a constant daily turnover of 1.5% of the creatine pool. The 
reversible and nonenzymatic cyclization of creatine to creatinine is pH and temperature 
dependent. Creatinine is excreted in urine and its daily excretion is directly proportional 
to the total body creatine pool. 
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Figure 2. Creatine metabolic pathway. 
Creatine metabolism and disease 
Primary creatine metabolism disorders- Cerebral Creatine Deficiency Syndromes 
Cerebral Creatine Deficiency Syndromes (CCDS) are a group of disorders 
consisting of defects in proteins involved in creatine biosynthesis, AGAT and GAMT, 





























forward primer, 5-GGCGGCGCGCGATCGAGGTCGGGTCGCCGT-3 and reverse primer, 
5-CGGGGCAGCCCCGGCCTCAGTTTCCCCTGC-3. Amplification was initiated after 15 
min Hotstart Taq (Qiagen) activation step at 95oC, followed by 38 cycles of denaturation, 
annealing and amplification (45 sec at 94oC, 45 sec at 60oC and, 1 min at 72oC). PCR products 
were purified (Millipore vacufold multiscreen PCR plates) and subsequently analyzed by 
SNaPshot.
The SNaPshot procedure was performed according to the instructions of the manufacturer 
(ABIPrism SNaPshot multiplex kit, Applied Biosystems) using a primer (5-
AGAACTGCAGCCCCGCGT-3) directly upstream of the nucleotide being involved in the 
mutation (c.59G>C; p.Trp20Ser). Calf intestinal phosphatase (CIP, 1U/�l) was used to remove 
excess of dNTP, ddNTP and primers. The SNaPshot reactions were resolved on a genetic 
analyzer in the GeneScan mode (ABI3100). In case a heterozygous mutation was detected by 
SNaPshot its presence was confirmed by direct DNA sequence analysis of an independent PCR 
product.
Transient transfection of GAMT-W20S ORF in HeLa cells 
The open reading frame (ORF) of the GAMT gene was cloned as described previously 14. In 
brief, the GAMT ORF containing the c.59G>C; p.Trp20Ser mutation was amplified by PCR 
using cDNA from a GAMT deficient fibroblast cell line containing the homozygous mutation 
with forward primer 5-CGCGCGATCGAGGTCGGGTC-3 and reverse primer 5-
GAAGCCGGGAAAGCTTCTGGTG-3. The PCR product was cloned in frame with Enhanced 
Green Fluorescent Protein (EGFP) in expression vector pEGFP-N1 (Clonetech). This construct 
(pEGFP-W20S), as well as, the empty vector (pEGFP-N1) and pEGFP-GAMT were then 
transiently transfected into HeLa cells as described previously (Almeida et al, 2006). Cell 
pellets for GAMT activity and Western blot were stored at -80ºC until further use.
The GAMT enzyme assay was performed according to Verhoeven et al 2004. To prove GAMT-
EGFP fusion protein expression, all lysates of the transfectants (30 �g) were separated in a 12% 
SDS-polyacrylamide gel and transferred to a Hybond� membrane by standard procedures. 
Immunodetection was performed using an anti-EGFP antibody and ECL detection kit 
(Amersham Biosciences). 
RESULTS  
Validation of the SNP detection by SNaPshot 
To ascertain that the SNaPshot procedure allows the detection of wild type c.59G, homozygous 
or heterozygous c.59G>C, the procedure was tested using the DNA isolated from a control, a 
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GAMT deficient patient (c.59G>C; p.Trp20Ser homozygous) and a carrier of the mutation 
(c.59G>C; p.Trp20Ser heterozygous). As illustrated in figure 2 the three genotypes are easily 
discriminated using SNaPshot.  
Figure 2. Detection of c.59G>C; p.Trp20Ser mutation using SNaPshot. Left panels illustrate 
the three electropherograms obtained using SNaPshot; right panels illustrate electropherograms 
of direct DNA sequencing confirmations. 
Carrier Rate of c.59G>C; p.Trp20Ser 
Blood spots from different regions of Portugal (Figure 1b), were screened for the c.59G>C; 
p.Trp20Ser mutation using SNaPshot. Eight heterozygous subjects were detected, suggesting a 
carrier rate of 0.8% (CI 0.2-1.3%). The highest frequency of heterozygous individuals was 
detected in the Archipelagos (Madeira and Açores islands, 4/238) and in Porto (2/192). In 
Coimbra and Lisboa one carrier was identified respectively (1/192 and 1/188). In the 
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